Detail
| LncRNA Name | C5orf66-AS1 |
| Synonyms | C5orf66-AS1, CTC-276P9.1, Epist |
| Region | GRCh38_5:135038831-135040047 Sequence |
| Ensembl | ENSG00000249082 |
| RefSeq | NR_105049 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✔ |
| Cancer Name | esophageal squamous cell cancer |
| ICD-0-3 | |
| Methods | Microarray, qRT-PCR, Western blot, Luciferase reporter assay |
| Sample | Primary ESCC tissues, esophageal cancer cell lines (TE1, TE13, T.Tn, YES2, Eca109, and Kyse170) |
| Expression Pattern | down-regulated |
| Function Description | Significant downregulation of CTC-276P9.1 was detected in esophageal cancer cells and ESCC tissues, and the expression of CTC-276P9.1 in ESCC tissues was associated with TNM stage, pathological differentiation, lymph node metastasis, and distant metastasis or recurrence.The aberrant hypermethylation of the regions around the transcription start site was more tumor specific and associated with the expression levels of CTC-276P9.1.histone modification may also participate in the regulation of CTC-276P9.1. Furthermore, over-expression of CTC-276P9.1 inhibited esophageal cancer cells proliferation and invasion in vitro, decreased the expression of proliferative markers and inhibited esophageal cancer cells invasion probably by regulating EMT. In addition, the dysregulation and hypermethylation of the regions around the transcription start site of CTC-276P9.1 were associated with poorer ESCC patients' survival. |
| Pubmed ID | 29524086 |
| Year | 2018 |
| Title | Aberrant methylation-mediated silencing of lncRNA CTC-276P9.1 is associated with malignant progression of esophageal squamous cell carcinoma. |
| External Links |
| Links for C5orf66-AS1 | GenBank HGNC lncrnadb Noncode |
| Links for esophageal squamous cell cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.